Scienmag

NOVEMBER 12, 2020

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

Immune Response 75

Immune Response Protein Clinical Trials Clinical Trials 75

Drug Discovery World

JANUARY 12, 2024

Research reveals an immune cell that can kill all cancers Researchers in the US have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.

Drugs 52

Drugs Immune Response Allergies Bacteria 52

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The failure of several late-stage trials highlights the challenging nature of HIV vaccine development. Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Scienmag

DECEMBER 9, 2020

Scientists have developed the first poliovirus […].

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. Related: Red Meat Allergy Test Gets FDA Clearance. “We The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Drug Discovery World

MARCH 23, 2023

The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID) and led by Mark M Davis, Director of the Stanford Institute for Immunity, Transplantation and Infection and a professor of microbiology and immunology at Stanford University School of Medicine in California.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

Scienmag

OCTOBER 9, 2020

Findings could lay the foundation for the development of effective therapeutic and malaria vaccine strategies, which has largely been hindered by a lack of understanding of the host immune response Credit: Aissatou Diawara Abu Dhabi, UAE, October 9, 2020: The Plasmodium parasite, which transmits malaria to humans through infected mosquitos, triggers (..)

Immune Response 52

Immune Response Gene Research Vaccination 52

Drug Discovery World

JANUARY 22, 2024

.” Andrea Bortolato , Director of Drug Discovery at SandboxAQ, will present: ‘Combining physics-based methods with AI solutions to maximise the probability of success and speed of drug discovery and development’. According to an article in Acta Pharmaceutica Sinica B , 90% of clinical drug development fails” 3.

Engineer 59

Engineer Immune Response Drugs Vaccination 59

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response.

Vaccination 54

Vaccination Vaccine Trials Immune Response 54

Scienmag

JUNE 27, 2021

The first human trial has shown no obvious side effects and a good immune response. Hiroshi Kiyono, CC BY 4.0 A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. Researchers based […].

Vaccination 72

Vaccination Vaccine Immune Response Trials 72

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. MIT researchers have now developed a vaccination strategy that can create an army of T cells that are […].

Vaccination 48

Vaccination Vaccine Immune Response Development 48

Scienmag

JULY 6, 2021

Researchers at Karolinska Institutet in Sweden publish new findings in the journal Cancer Discovery showing how pharmacological activation of the protein p53 boosts the immune response against tumours. Given its ability to react […].

Immune Response 40

Immune Response Protein Development Research 40

The Pharma Data

MARCH 31, 2022

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. Fauci, M.D. Investigators aim to have initial findings available by August 2022.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

The Pharma Data

SEPTEMBER 1, 2020

The company has been developing the vaccine in partnership with Oxford University, and has said it is recruiting up to 30,000 adults over the age of 18 across a broad spectrum of racial, ethnic and geographic groups who are healthy or have steady underlying conditions. . Conor Kavanagh. Source link.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Scienmag

DECEMBER 22, 2020

Study provides insights that could inform vaccine timing and improve care BOSTON — Pregnant women may be especially vulnerable to developing more severe cases of COVID-19 following SARS-CoV-2 infection, but little is known about their anti-SARS-CoV-2 immune response or how it may affect their offspring.

Immune Response 40

Immune Response Antibody Vaccination Vaccine 40

Scienmag

DECEMBER 16, 2020

BOSTON — Understanding the body’s immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines. Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19.

Antibody 40

Antibody Immune Response Scientist Vaccination 40

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID).

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added. .

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

AUGUST 13, 2020

In a press statement , Kaiser Permanente outlined that in this phase of the trial, data will be collected about the safety, immune response and efficacy of the vaccine candidate as required for regulatory review.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain. The post FDA clears Dupixent as first drug for rare skin disorder appeared first on.

Drugs 67

Drugs Immune Response Allergies Sales 67

pharmaphorum

JULY 7, 2022

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. Building blocks. Identifying the threat.

Vaccination 86

Vaccination Vaccine Development Research 86

The Pharma Data

JANUARY 17, 2021

The drug is being developed for several indications, but the NDA is for lupus nephritis (LN), a serious inflammation of the kidneys the result of systemic lupus erythematosus (SLE). By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses.

Manufacturing 52

Manufacturing Immune Response Allergies Drugs 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of INO-4800. Department of Defense.

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ Allergy, 75: 100-119. Arthritis Rheumatol.

Trials 52

Trials Immune Response Allergies Clinical Trials 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

OCTOBER 26, 2020

The National Institute of Allergy and Infectious Diseases (NIAID), the study sponsor, could not verify the safety issue, but their analysis also indicated there was little likelihood the antibody would help the hospitalized patients. Histogen and Amerimmune signed a deal to develop and commercialize emricasan for the treatment of COVID-19.

Antibody 52

Antibody Vaccination Vaccine Manufacturing 52

Pharmaceutical Technology

JUNE 16, 2023

The developer has tested OVX836 in four completed clinical trials. In a company statement announcing the latest trial kick-off, Osivax said a recently completed separate Phase IIa trial demonstrated that the candidate in combination with QIVs had a good safety profile with no impairment of immune response by the QIVs.

Vaccination 246

Vaccination Vaccine Trials Immune Response 246

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. Since April 2020, Mymetics’ goal is to develop a safe and highly effective virosome-based Covid-19 vaccine that can be easily administered to all age groups, particularly to immune compromised and elderly populations.

Vaccination 40

Vaccination Vaccine Containment Immune Response 40

XTalks

MAY 2, 2024

Some treatments already on the market have grabbed additional approvals in 2024, including Novo Nordisk’s Wegovy (semaglutide) for cardiovascular risk reduction, Dupixent (dupilumab) for eosinophilic esophagitis (EoE) in young children and Xolair (omalizumab) for food allergies. to develop and commercialize acoramidis in Japan.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

Delveinsight

JANUARY 21, 2021

These will come out of Merus’ so-called Biclonics platform that develops CD3-engaging, T-cell redirecting bispecific antibody therapies. chief operating officer of Loxo Oncology, said that CD3-engaging bispecific antibodies are soon becoming one of the most transformative immune-modulating modalities used for cancer treatment.

Research 52

Research Protein Clinical Trials Clinical Trials 52

Bioengineer

JULY 15, 2021

.” Immunotherapy has revolutionized cancer treatment by helping patients’ immune systems fight off cancer. Boosted by the immunotherapy, the immune cells attacked the cancer cells that had been damaged by the radiotherapy. This agent was developed by one of the co-authors, Jamey Weichert, Ph.D., ” ###.

Medicine 52

Medicine Clinical Trials Clinical Trials Scientist 52

Pfizer

JULY 26, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. IMPORTANT SAFETY INFORMATION . has a fever.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Drug Discovery World

FEBRUARY 3, 2023

A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

Drug Discovery World

FEBRUARY 1, 2023

An experimental vaccine against Marburg virus (MARV) was proved to be safe and induced an immune response in a small, first-in-human clinical trial. MARV, a filovirus in the same family as Ebola virus, causes a rapidly progressive febrile illness that leads to shock and death in a large proportion of infected individuals.

Vaccination 52

Vaccination Vaccine Immune Response Clinical Trials 52

pharmaphorum

NOVEMBER 8, 2021

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. Over the eight-month follow-up period, there were zero hospitalisations for COVID-19 in the REGEN-COV group, compared to six in a matched placebo arm. .

Antibody 102

Antibody Vaccination Vaccine Immune Response 102